Early pregnancy prediction of preeclampsia in nulliparous women, combining clinical risk and biomarkers: The Screening for Pregnancy Endpoints (SCOPE) international cohort study

Hypertension

Volumn 64, Issue 3, 2014, Pages 644-652

  Kenny, Louise C ^a   Black, Michael A ^b   Poston, Lucilla ^c   Taylor, Rennae ^d   Myers, Jenny E ^f   Baker, Philip N ^d,e,g   McCowan, Lesley M ^d,e   Simpson, Nigel A B ^h   Dekker, Gus A ^i,j   Roberts, Claire T ^i,j   Rodems, Kelline ^k   Noland, Brian ^k   Raymundo, Michael ^k   Walker, James J ^h   North, Robyn A ^c  

^a UNIVERSITY COLLEGE CORK   (Ireland)

^b UNIVERSITY OF OTAGO   (New Zealand)

^c KING'S COLLEGE LONDON   (United Kingdom)

^d THE UNIVERSITY OF AUCKLAND   (New Zealand)

^e UNIVERSITY OF AUCKLAND   (New Zealand)

^f UNIVERSITY OF MANCHESTER   (United Kingdom)

^g Division of Medicine Emergency and Integrated Care   (New Zealand)

^h UNIVERSITY OF LEEDS   (United Kingdom)

ⁱ LYELL MCEWIN HOSPITAL   (Australia)

^j UNIVERSITY OF ADELAIDE   (Australia)

^k Alere   (United States)

more..

Author keywords

Biological markers; Diagnosis; Preeclampsia; Pregnancy

Indexed keywords

ANGIOGENIN; BIOLOGICAL MARKER; BRAIN NATRIURETIC PEPTIDE; C REACTIVE PROTEIN; CYSTATIN C; ELAFIN; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; LEPTIN; LEPTIN RECEPTOR; PLACENTAL GROWTH FACTOR; PREGNANCY ASSOCIATED PLASMA PROTEIN A; TISSUE INHIBITOR OF METALLOPROTEINASE 1;

ANGIOGENESIS; ARTICLE; BODY MASS; COHORT ANALYSIS; CONTROLLED STUDY; FEMALE; FIRST TRIMESTER PREGNANCY; HUMAN; LOW RISK POPULATION; MAJOR CLINICAL STUDY; MEAN ARTERIAL PRESSURE; NULLIPARA; OUTCOME ASSESSMENT; PREDICTION; PREECLAMPSIA; PREGNANCY; PREGNANCY OUTCOME; PREGNANT WOMAN; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RISK FACTOR; SCREENING FOR PREGNANCY ENDPOINT; SCREENING TEST; SMALL FOR DATE INFANT; UTERINE ARTERY;

BIOLOGICAL MARKERS; DIAGNOSIS; PREECLAMPSIA; PREGNANCY;

ADULT; BIOLOGICAL MARKERS; BLOOD PRESSURE; BODY MASS INDEX; COHORT STUDIES; FEMALE; HUMANS; INTERNATIONAL COOPERATION; MASS SCREENING; MODELS, STATISTICAL; PARITY; PRE-ECLAMPSIA; PREDICTIVE VALUE OF TESTS; PREGNANCY; PREGNANCY PROTEINS; RANDOM ALLOCATION; RIBONUCLEASE, PANCREATIC; RISK FACTORS; VASCULAR RESISTANCE;

EID: 84907322551     PISSN: 0194911X     EISSN: 15244563     Source Type: Journal    
DOI: 10.1161/HYPERTENSIONAHA.114.03578     Document Type: Article

References (42)

1. Sibai B, Dekker G, Kupferminc M. Pre-eclampsia. Lancet. 2005;365:785-799.
2. Khan KS, Wojdyla D, Say L, Gülmezoglu AM, Van Look PF. WHO analysis of causes of maternal death: A systematic review. Lancet. 2006;367:1066-1074.
3. Sibai BM. Preeclampsia as a cause of preterm and late preterm (nearterm) births. Semin Perinatol. 2006;30:16-19.
4. Bellamy L, Casas JP, Hingorani AD, Williams DJ. Pre-eclampsia and risk of cardiovascular disease and cancer in later life: systematic review and meta-analysis. BMJ. 2007;335:974.
5. Valdés G, Quezada F, Marchant E, von Schultzendorff A, Morán S, Padilla O, Martínez A. Association of remote hypertension in pregnancy with coronary artery disease: A case-control study. Hypertension. 2009;53:733-738.
6. National Institute for Health and Clinical Excellence. Hypertension in Pregnancy: The Management of Hypertensive Disorders During Pregnancy. Manchester, United Kingdom: National Institute for Health and Clinical Excellence; 2010 (revised January 2011).
7. Duley L, Henderson-Smart DJ, Meher S, King JF. Antiplatelet agents for preventing pre-eclampsia and its complications. Cochrane Database Syst Rev. 2007:CD004659.
8. Steegers EA, von Dadelszen P, Duvekot JJ, Pijnenborg R. Pre-eclampsia. Lancet. 2010;376:631-644.
9. North RA, McCowan LM, Dekker GA, Poston L, Chan EH, Stewart AW, Black MA, Taylor RS, Walker JJ, Baker PN, Kenny LC. Clinical risk prediction for pre-eclampsia in nulliparous women: development of model in international prospective cohort. BMJ. 2011;342:d1875.
10. Meads CA, Cnossen JS, Meher S, Juarez-Garcia A, terRiet G, Duley L, Roberts TE, Mol BW, vander Post JA, Leeflang MM, Barton PM, Hyde CJ, Gupta JK, Khan KS. Methods of prediction and prevention of preeclampsia: systematic reviews of accuracy and effectiveness literature with economic modelling. Health Technol Assess. 2008;12:iii-iv, 1.
11. Poon LC, Kametas NA, Maiz N, Akolekar R, Nicolaides KH. Firsttrimester prediction of hypertensive disorders in pregnancy. Hypertension. 2009;53:812-818.
12. Powers RW, Roberts JM, Plymire DA, Pucci D, Datwyler SA, Laird DM, Sogin DC, Jeyabalan A, Hubel CA, Gandley RE. Low placental growth factor across pregnancy identifies a subset of women with preterm preeclampsia: Type 1 versus type 2 preeclampsia? Hypertension. 2012;60:239-246.
13. Anderson UD, Olsson MG, Kristensen KH, Åkerström B, Hansson SR. Review: Biochemical markers to predict preeclampsia. Placenta. 2012;33(suppl):S42-S47.
14. Levine RJ, Maynard SE, Qian C, Lim KH, England LJ, Yu KF, Schisterman EF, Thadhani R, Sachs BP, Epstein FH, Sibai BM, Sukhatme VP, Karumanchi SA. Circulating angiogenic factors and the risk of preeclampsia. N Engl J Med. 2004;350:672-683.
15. McCowan L, North RA, Taylor R. Screening for pregnancy endpoints: preeclampsia, growth restricted baby and spontaneous preterm birth. Actrn12607000551493. Australia New Zealand Clinical Trial Registry. 2007. https://www.anzctr.org.au/Trial/Registration/TrialReview.aspx?id=82254. Accessed June 18, 2014.
16. Team RC. R: A Language and Environment for Statistical Computing. Vienna, Austria: R Foundation for Statistical Computing; 2013.
17. Schwarz GE. Estimating the dimension of a model. Ann Stat. 1978;6:461-464.
18. Tomas J, Developer A. Epitools: Epidemiology Tools. R Package Version 0.5-7. Vienna, Austria: R Foundation for Statistical Computing; 2012.
19. Robin X, Turck N, Hainard A, Tiberti N, Lisacek F, Sanchez JC, Müller M. pROC: An open-source package for R and S+ to analyze and compare ROC curves. BMC Bioinformatics. 2011;12:77.
20. Andraweera PH, Dekker GA, Roberts CT. The vascular endothelial growth factor family in adverse pregnancy outcomes. Hum Reprod Update. 2012;18:436-457.
21. Zhou Y, McMaster M, Woo K, Janatpour M, Perry J, Karpanen T, Alitalo K, Damsky C, Fisher SJ. Vascular endothelial growth factor ligands and receptors that regulate human cytotrophoblast survival are dysregulated in severe preeclampsia and hemolysis, elevated liver enzymes, and low platelets syndrome. Am J Pathol. 2002;160:1405-1423.
22. Chappell LC, Seed PT, Briley A, Kelly FJ, Hunt BJ, Charnock-Jones DS, Mallet AI, Poston L. A longitudinal study of biochemical variables in women at risk of preeclampsia. Am J Obstet Gynecol. 2002;187:127-136.
23. Taylor RN, Grimwood J, Taylor RS, McMaster MT, Fisher SJ, North RA. Longitudinal serum concentrations of placental growth factor: evidence for abnormal placental angiogenesis in pathologic pregnancies. Am J Obstet Gynecol. 2003;188:177-182.
24. Myatt L, Clifton RG, Roberts JM, Spong CY, Wapner RJ, Thorp JM Jr, Mercer BM, Peaceman AM, Ramin SM, Carpenter MW, Sciscione A, Tolosa JE, Saade G, Sorokin Y, Anderson GD. Can changes in angiogenic biomarkers between the first and second trimesters of pregnancy predict development of pre-eclampsia in a low-risk nulliparous patient population? BJOG. 2013;120:1183-1191.
25. Rana S, Karumanchi SA, Lindheimer MD. Angiogenic factors in diagnosis, management, and research in preeclampsia. Hypertension. 2014;63:198-202.
26. Akolekar R, Syngelaki A, Poon L, Wright D, Nicolaides KH. Competing risks model in early screening for preeclampsia by biophysical and biochemical markers. Fetal Diagn Ther. 2013;33:8-15.
27. Shaarawy M, Al-Sokkary F, Sheba M, Wahba O, Kandil HO, Abdel-Mohsen I. Angiogenin and vascular endothelial growth factor in pregnancies complicated by preeclampsia. Int J Gynaecol Obstet. 2005;88:112-117.
28. Groom KM, North RA, Poppe KK, Sadler L, McCowan LM. The association between customised small for gestational age infants and pre-eclampsia or gestational hypertension varies with gestation at delivery. BJOG. 2007;114:478-484.
29. Ridker PM, Hennekens CH, Buring JE, Rifai N. C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. N Engl J Med. 2000;342:836-843.
30. Kenny LC, Broadhurst DI, Dunn W, Brown M, North RA, McCowan L, Roberts C, Cooper GJ, Kell DB, Baker PN. Robust early pregnancy prediction of later preeclampsia using metabolomic biomarkers. Hypertension. 2010;56:741-749.
31. Lee J, Romero R, Dong Z, Lee DC, Dong Y, Mittal P, Chaiworapongsa T, Hassan SS, Kim CJ. Glycogen phosphorylase isoenzyme BB plasma concentration is elevated in pregnancy and preterm preeclampsia. Hypertension. 2012;59:274-282.
32. Tuffnell DJ, Jankowicz D, Lindow SW, Lyons G, Mason GC, Russell IF, Walker JJ. Outcomes of severe pre-eclampsia/eclampsia in yorkshire 1999/2003. BJOG. 2005;112:875-880.
33. Liu S, Joseph KS, Liston RM, Bartholomew S, Walker M, Leon JA, Kirby RS, Sauve R, Kramer MS. Incidence, risk factors, and associated complications of eclampsia. Obstet Gynecol. 2011;118:987-994.
34. Roberge S, Giguère Y, Villa P, Nicolaides K, Vainio M, Forest JC, von Dadelzen P, Vaiman D, Tapp S, Bujold E. Early administration of lowdose aspirin for the prevention of severe and mild preeclampsia: A systematic review and meta-analysis. Am J Perinatol. 2012;29:551-556.
35. Smith GC. Researching new methods of screening for adverse pregnancy outcome: lessons from pre-eclampsia. PLoS Med. 2012;9:e1001274.
36. Deeks JJ. Systematic reviews in health care: Systematic reviews of evaluations of diagnostic and screening tests. BMJ. 2001;323:157-162.
37. Park CW, Park JS, Shim SS, Jun JK, Yoon BH, Romero R. An elevated maternal plasma, but not amniotic fluid, soluble fms-like tyrosine kinase-1 (sFlt-1) at the time of mid-trimester genetic amniocentesis is a risk factor for preeclampsia. Am J Obstet Gynecol. 2005;193(3 pt 2): 984-989.
38. Wathén KA, Tuutti E, Stenman UH, Alfthan H, Halmesmäki E, Finne P, Ylikorkala O, Vuorela P. Maternal serum-soluble vascular endothelial growth factor receptor-1 in early pregnancy ending in preeclampsia or intrauterine growth retardation. J Clin Endocrinol Metab. 2006;91:180-184.
39. Baumann MU, Bersinger NA, Mohaupt MG, Raio L, Gerber S, Surbek DV. First-trimester serum levels of soluble endoglin and soluble fms-like tyrosine kinase-1 as first-trimester markers for late-onset preeclampsia. Am J Obstet Gynecol. 2008;199:2661-2666.
40. McKeeman GC, Ardill JE, Caldwell CM, Hunter AJ, McClure N. Soluble vascular endothelial growth factor receptor-1 (sFlt-1) is increased throughout gestation in patients who have preeclampsia develop. Am J Obstet Gynecol. 2004;191:1240-1246.
41. Poon LC, Syngelaki A, Akolekar R, Lai J, Nicolaides KH. Combined screening for preeclampsia and small for gestational age at 11-13 weeks. Fetal Diagn Ther. 2013;33:16-27.
42. Myatt L, Clifton RG, Roberts JM, et al. First-trimester prediction of preeclampsia in nulliparous women at low risk. Obstet Gynecol. 2012;119:1234-1242.